留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

脐带间充质干细胞治疗难治性慢性移植物抗宿主病的疗效观察

张玲 张祥忠 李晓青 龙冰 林东军 李旭东

张玲, 张祥忠, 李晓青, 等. 脐带间充质干细胞治疗难治性慢性移植物抗宿主病的疗效观察[J]. 器官移植, 2016, 7(6): 459-462. doi: 10.3969/j.issn.1674-7445.2016.06.009
引用本文: 张玲, 张祥忠, 李晓青, 等. 脐带间充质干细胞治疗难治性慢性移植物抗宿主病的疗效观察[J]. 器官移植, 2016, 7(6): 459-462. doi: 10.3969/j.issn.1674-7445.2016.06.009
Zhang Ling, Zhang Xiangzhong, Li Xiaoqing, et al. Clinical efficacy of umbilical cord-derived menchymal stem cell treatment of refractory chronic graft-versus-host disease[J]. ORGAN TRANSPLANTATION, 2016, 7(6): 459-462. doi: 10.3969/j.issn.1674-7445.2016.06.009
Citation: Zhang Ling, Zhang Xiangzhong, Li Xiaoqing, et al. Clinical efficacy of umbilical cord-derived menchymal stem cell treatment of refractory chronic graft-versus-host disease[J]. ORGAN TRANSPLANTATION, 2016, 7(6): 459-462. doi: 10.3969/j.issn.1674-7445.2016.06.009

脐带间充质干细胞治疗难治性慢性移植物抗宿主病的疗效观察

doi: 10.3969/j.issn.1674-7445.2016.06.009
详细信息
    通讯作者:

    李旭东. E-mail:13631359815@139.com.

  • 中图分类号: R617, R551

Clinical efficacy of umbilical cord-derived menchymal stem cell treatment of refractory chronic graft-versus-host disease

More Information
  • 摘要:   目的   探讨脐带来源间充质干细胞(MSC)治疗异基因造血干细胞移植术后难治性慢性移植物抗宿主病(cGVHD)的疗效及安全性。   方法   7例恶性血液病患者接受异基因造血干细胞移植术后出现cGVHD,常规免疫抑制剂治疗无效,在原有免疫抑制剂基础上给予脐带来源MSC治疗,细胞数1×106/kg,每周1次,共4次。观察其疗效、安全性和患者存活情况。   结果   7例患者接受MSC输注后,2例获得完全缓解(CR),3例部分缓解(PR),总有效5例(5/7),2例无效(NR)。未发现输注相关不良反应,无患者出现原发病复发。1例患者部分缓解后继发巨细胞病毒肺炎,死于重症肺炎,其余病例均存活。   结论   脐带MSC对于治疗难治性cGVHD具有一定的疗效,且输注过程安全。

     

  • 图  1  7例恶性血液病患者异基因HSCT后生存情况

    Figure  1.  Survival situation of 7 patients with malignant hematologic disease after allo-HSCT

    表  1  脐带MSC治疗后疗效评价

    Table  1.   Efficacy evaluation of human umbilical cord MSC therapy

    病例性别年龄(岁)诊断受累器官合用药物MSC输注次数疗效
    144急性淋巴细胞白血病肝脏、口腔西罗莫司、甲泼尼龙4CR
    231急性髓细胞白血病皮肤、口腔西罗莫司、甲泼尼龙4CR
    338急性髓细胞白血病皮肤甲泼尼龙4PR
    442急性淋巴细胞白血病眼、口腔、皮肤甲泼尼龙4PR
    543非霍奇金淋巴瘤肝脏他克莫司、甲泼尼龙4PR
    632急性混合细胞白血病肺、肾甲泼尼龙3NR
    727急性髓细胞白血病皮肤泼尼松4NR
    下载: 导出CSV
  • [1] Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research[J]. Biol Blood Marrow Transplant, 2015, 21(2): 266-274. doi: 10.1016/j.bbmt.2014.10.021
    [2] Herrmann R, Sturm M, Shaw K, et al. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study[J]. Int J Hematol, 2012, 95(2):182-188. doi: 10.1007/s12185-011-0989-2
    [3] Gao F, Chiu SM, Motan DA, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects[J]. Cell Death Dis, 2016,7: e2062. doi: 10.1038/cddis.2015.327
    [4] Lee SJ, Wolff D, Kitko C, et al. Measuring therapeutic response in chronic graft-versus-host disease. national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: Ⅳ. the 2014 Response Criteria Working Group report[J]. Biol Blood Marrow Transplant, 2015, 21(6): 984-999. doi: 10.1016/j.bbmt.2015.02.025
    [5] Le Blanc K, Rasmusson I, Sunberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells[J]. Lancet, 2004, 363 (9419): 1439-1441. doi: 10.1016/S0140-6736(04)16104-7
    [6] Liu JJ, Li D, Ju X, et al. Umbilical cord-derived mesenchymal stem cells retain immunomodulatory and anti-oxidative activities after neural induction[J]. Neural Regen Res, 2012, 7(34): 2663-2672. http://cn.bing.com/academic/profile?id=1510063224&encoded=0&v=paper_preview&mkt=zh-cn
    [7] Zhou J, Tian G, Wang J, et al. Neural cell injury microenvironment induces neural differentiation of human umbilical cord mesenchymal stem cells[J]. Neural Regen Res, 2012, 7(34): 2689-2697.
    [8] 孙燕玲,李旭东,林东军,等. 非血缘脐血移植治疗高危急性白血病的临床研究[J]. 器官移植, 2015, 6(6): 420-424. http://www.organtranspl.com/browse/detail/qkid/89/id/150.html

    YL, Li XD, Lin DJ, et al. Clinical study on treatment of high-risk acute leukemia with unrelated cord blood transplantation[J]. Organ Transplant, 2015, 6(6): 420-424. http://www.organtranspl.com/browse/detail/qkid/89/id/150.html
    [9] Gao L, Zhang Y, Hu B, et al. Phase Ⅱ multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation[J]. J Clin Oncol, 2016, 34 (24): 2834-2850. http://cn.bing.com/academic/profile?id=2460851798&encoded=0&v=paper_preview&mkt=zh-cn
    [10] Introna M, Lucchini G, Dander E, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase Ⅰ study on 40 adult and pediatric patients[J]. Biol Blood Marrow Transplant, 2014, 20(3) 375-381. doi: 10.1016/j.bbmt.2013.11.033
    [11] 黄英丹,肖翠容,林进宗,等. 脐带来源间充质干细胞治疗异基因造血干细胞移植后慢性移植物抗宿主病[J]. 中国组织工程研究,2014, 18(50): 8093-8097. http://www.cnki.com.cn/Article/CJFDTOTAL-XDKF201450012.htm

    Huang YD, Xiao CR, Lin JZ, et al. Treatment of chronic graft-versus-host disease with human umbilical cord mesenchymal stem cells[J]. Chin J Tissue Eng Res, 2014,18 (50): 8093- 8097. http://www.cnki.com.cn/Article/CJFDTOTAL-XDKF201450012.htm
    [12] 卢荣标,陆春. 移植物抗宿主疾病皮肤损害的治疗进展[J]. 器官移植, 2013 , 4 (3) : 169-176. http://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ201303012.htm

    Lu RB, Lu C. Therapeutic advance in cutaneous graft-versus-host disease[J]. Organ Transplant,2013,4(3):169-176. http://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ201303012.htm
    [13] Weng JY, Du X, Geng SX, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD[J]. Bone Marrow Trasplant, 2010, 45(12): 1732-1740. doi: 10.1038/bmt.2010.195
    [14] Lazarus HM, Pavletic SZ. Umbilical cord blood-derived mesenchymal stromal cells for reducing chronic graft-versus-host disease after haploidentical transplantation: just another labor-intensive strategy, or showing the way?[J]. J Clin Oncol, 2016, 34 (24): 2812-2813. doi: 10.1200/JCO.2016.67.7344
    [15] Kim N, Im KI, Lim JY, et al. Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice[J]. Ann Hematol, 2013, 92(10): 1295-1308. doi: 10.1007/s00277-013-1796-z
    [16] Kuzmina LA, Petinati NA, Parovichnikova EN, et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft-versus-host disease-a phase Ⅱ study[J]. Stem Cells Int, 2012: 968213. http://cn.bing.com/academic/profile?id=2126957024&encoded=0&v=paper_preview&mkt=zh-cn
    [17] Liu K, Chen Y, Zeng Y, et al. Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study[J]. Stem Cells Dev, 2011, 20(10): 1679-1685. doi: 10.1089/scd.2010.0447
    [18] Zhao K, Lou R, Huang F, et al. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2015, 21(1): 97-104. doi: 10.1016/j.bbmt.2014.09.030
  • 加载中
图(1) / 表(1)
计量
  • 文章访问数:  234
  • HTML全文浏览量:  75
  • PDF下载量:  12
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-08-16
  • 网络出版日期:  2021-03-19
  • 刊出日期:  2016-11-15

目录

    /

    返回文章
    返回